Ozempic maker takes $107 billion hit as alarm bells ring louder
Novo named Maziar Mike Doustdar as its new chief executive, turning to a veteran insider to revive sales and reassure investors rattled by fears the Danish drugmaker is losing ground in the obesity drug race it started.
Doustdar's appointment failed to stem a stock market rout sparked by Novo slashing its outlook for 2025 sales growth to between 8 per cent and 14 per cent, from between 13 per cent and 21 per cent previously. Its shares plunged nearly 30 per cent before paring some losses to trade down over 20 per cent by mid-afternoon. The shares are now down 44 per cent this year.
'The magnitude of the guidance cut is a shocker,' Markus Manns, a portfolio manager at mutual fund firm Union Investment, a Novo shareholder, told Reuters, adding that Novo's issues went deeper than 'compounded' copycats to Wegovy.
Compounded drugs are custom-made medicines that are based on the same ingredients as branded drugs.
Novo has been hit by copycats of its GLP-1 drugs Wegovy for weight-loss and Ozempic for diabetes. US law bars pharmacies from replicating approved drugs, but has allowed 'compounding' for patients needing custom doses or formulations.
Loading
The company said in a statement that it cut its 2025 sales outlook due to lower growth expectations in the second half in the US, both for Wegovy and Ozempic in the GLP-1 diabetes market.
The drugmaker, which became Europe's most valuable listed company following the launch of Wegovy in 2021, is now facing a reckoning as it looks to turn things around after the abrupt removal in May of CEO Lars Fruergaard Jorgensen.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
7NEWS
2 hours ago
- 7NEWS
Experimental pill helps patients shed 12 per cent of body weight
Eli Lilly says its experimental GLP-1 pill helped patients lose 12.4 per cent of their body weight after 72 weeks in a late-stage study. Unlike injectable obesity drugs, which are peptides designed to mimic the appetite-controlling GLP-1 hormone, orforglipron is a small molecule pill that is easier to manufacture and package, said Kenneth Custer, president of Lilly's cardiometabolic health division. Lilly, whose injectable GLP-1 Zepbound competes directly with Wegovy, views the once-daily pill as a promising alternative to injections that could be used for early intervention and long-term disease management, Custer said. 'We have pretty big aspirations for how many patients orforglipron could help,' he said, adding that Lilly still expects to file for regulatory approvals of the once-daily pill before the end of the year. In the study of more than 3000 overweight or obese adults with weight-related health issues, but not diabetes, those who received the highest 36 milligram dose of orforglipron on average shed 12.4 per cent of their weight versus 0.9 per cent for those who received a placebo. Patients on a six-milligram dose of the Lilly drug lost 7.8 per cent of their weight. The most common side effects seen in the study were mild-to-moderate gastrointestinal issues. The rate of nausea for high-dose patients was 33.7 per cent, while 24 per cent experienced vomiting, compared with 10.4 per cent and 3.5 per cent, respectively for the placebo group. Just over 10 per cent of the high-dose patients dropped out of the trial due to adverse side effects. No liver safety issues were seen, Lilly said. Custer said orforglipron can be taken without restrictions on food and water. Lilly said orforglipron also lowered markers of heart disease risk, including cholesterol, triglycerides, and blood pressure, across all doses. Lilly has also said it has begun manufacturing the drug in order to stockpile supply ahead of a commercial launch, which should help avoid shortages experienced when early demand for the injectables far outstripped supply. The full results from the Lilly-backed trial will be presented next month at a major European diabetes meeting, the Indianapolis-based drugmaker said.
West Australian
11 hours ago
- West Australian
Bonanza grade gold in rock chips for Infinity in northern NSW
Infinity Mining has reported bumper gold in rock chips results from its latest Sir Walter Scott gold prospect in northern New South Wales, reporting gold grades up to 68.6 grams per tonne (g/t) gold in samples near its historic gold workings. The company collected 12 rock chip samples in early July from its newest Sir Walter Scott target area, just 3 kilometres south of its flagship Cangai copper project. Six of the samples returned high-grade gold results. The samples occurred along a 1km northwest-trending structural corridor, with standout results of 68.6g/t gold, 23.3g/t and a further 9.19g/t sample. The recently identified area features historic mine workings and has become a growing focus of Infinity's eastern Australian portfolio. It is 3km east of neighbour Novo Resources' historic John Bull mine, within the same interpreted but never-drilled structural corridor. The company says its high-grade assays occurred in laminated quartz veins exhibiting minor sulphides, such as pyrite, galena and sphalerite, aligning with sampling from the 1980s. The Sir Walter Scott prospect was discovered in 1872 and historically produced 1790 ounces of gold from 2203 tonnes of ore at an average head grade of about 25g/t gold, or nearly an ounce per tonne of dirt. Hosted within the carboniferous Gundahl complex, the mineralisation occurs in quartz-sulphide veins within steeply dipping chloritic shear zones. The company hopes the prospect is part of a larger intrusion-related gold system, a hypothesis also proposed for Novo's nearby John Bull gold project. Novo recently reported anomalous rock chip samples and drill intercepts at John Bull, with promising peak assays up to 67.9g/t gold – nearly as good as Infinity's. Infinity believes that its latest results, coupled with the lack of modern exploration at Sir Walter Scott, position the prospect as a compelling target for further work. A follow-up field program is slated for the coming months, focusing on detailed geological and structural mapping alongside surface geochemical sampling to verify historical results and better define future potential drill targets. The company is also focussed on its flagship Cangai copper mine, to Sir Walter's north. The project is one of the highest-grade copper mines in NSW, hosting a 4.4-million-tonne resource at 2.5 per cent copper. It also has credits for zinc, gold and silver, typical of a volcanogenic massive sulphide deposit. Cangai produced 4950t of copper, 52.7 kilograms of gold and 1035kg of silver from 77,000t of ore, making it one of NSW's highest-grade and most successful early 20th-century copper mines. Infinity's broader portfolio spans 3700 square kilometres across NSW's Macquarie Arc, Victoria's Melbourne Zone and Western Australia's East Pilbara and Central Goldfields. With gold prices remaining strong, the company's focus on its eastern Australian assets positions Infinity to capitalise on a first potential drilling program at Sir Walter Scott. The follow-up results will be key, however for now, it looks like Infinity could be well on the way to a new NSW gold discovery. Is your ASX-listed company doing something interesting? Contact:
West Australian
2 days ago
- West Australian
HelloFresh is investing $US70 million to have AI help plan dinner
Meal kit specialists HelloFresh is employing artificial intelligence to get more customers cooking. The Berlin-based company announced on Monday a $US70 million ($108.45m) investment in its menu subscriptions. The funds will more than double the number of meals on offer and increase the range of star proteins such as beef and seafood. It will also bolster the use of AI technology to streamline decision making during ordering, even as the choices for recipes increase. The refresh is taking place for customers in the US, its biggest market; the company says it will enhance product offerings in other countries at a later date. In 2024, the group delivered over 511 million meals in North America, which also includes Canada. The investment is intended to enhance brand loyalty and bring in customers in the face of inflationary food pressures, says Assaf Ronen, HelloFresh group president in an exclusive interview with Bloomberg. While '$US70 million is a very large check,' he says, 'the more we invest in customers, the more they stay with us.' HelloFresh sees opportunity as Americans cut back on dining out amid rising food prices. The company is currently valued at around €1.5 billion; at its peak in 2021, it hit €16.7 billion as a result of the pandemic. According to a series of recent company polls, including one among 5000 customers, nine out of 10 respondents said they're planning to eat more at home in the upcoming year. And 58 per cent of respondents said they're bored with what they eat every night. To that end, a major portion of that $US70 million will be used for a broad expansion of weekly meal offerings, from 45 to more than 100. Customers will now be able to start cooking dishes like seared salmon with couscous, spiced vegetables and lemon yogurt, and eggplant caponata pitas with mozzarella. There's more premium meat cuts, including grass-fed rib-eyes and whole chicken thighs, and triple the amount of seafood will be available with no upcharge; depending on location, subscription prices might range from about $US60 for two two-serving recipes per week, including delivery, to about $US370 for six recipes for six people weekly. The cost-per-serving runs from about $US10 to $US11.50. The company is also including the option of more seasonal produce and more specialty products, like nutritional yeast and kimchi. Upcharges will be in place for options like multi-course meals and platters. Portion sizes will also generally increase, says Mr Ronen (look no further than Reddit's HelloFresh thread if you want to discuss). Some sides will increase by 50 per cent while some proteins will be 20 per cent bigger. There will also be increased customisable options for swapping out ingredients, like chicken for pork. Mr Ronen, who was vice president of the Alexa division at a decade ago, says AI technology will help customers navigate the expanded menus and prioritise selections. 'What's at the top of your list will be more relevant for you.' The more each customer orders, the more the system will Netflix-style prompt meals that reflect your preferences-for instance, recipes that take five minutes versus 50 minutes in the kitchen. Mr Ronen won't confirm how much meal prices will go up in response to these improvements, but he says when they take effect in September, they won't be relatively higher than price increases in the broader economy. 'Pricing is something we're always looking at. In some places, there is a price increase, but it's lower than the rise in inflationary food prices,' he says. Upgrades in HelloFresh's 30-plus distribution centers worldwide will also be implemented with the investment. The company will install humanoid-style robots in warehouses to speed up the meal kit packing. In the future, Mr Ronen says HelloFresh will increase its use of robotics: 'We look at this refresh as our big first step but not as a last step.' He claims that there's no plan to cut the company's workforce. But 'the more we do, the more we need robots to meet demand. It's about not needing to grow employees three times' in the future. Or, he says, 'its just going to take people longer to get their meals.' The Washington Post
